Inovio looks to raise up to $125M; Sunesis sets sights on $43M: Epizyme earns $2M milestone from GSK;

@FierceBiotech: Radius Health looks to catch the IPO wave with $86M pitch. News | Follow @FierceBiotech

@JohnCFierce: Generics manufacturing--the "Wild West." I'm telling you, this is a scandal in the making. Piece via Bloomberg | Follow @JohnCFierce

@DamianFierce: Analyst: Merck's PD-1 promise could heap $5B on 2020 revenue. Story | Follow @DamianFierce

@EmilyMFierce: NIH makes new database on age-related diseases available to researchers. Item | Follow @EmilyMFierce

> Blue Bell, PA-based Inovio Pharmaceuticals ($INO) has filed to sell up to $125 million in shares periodically to help fund its work on DNA-based vaccines. Report

> South San Francisco-based Sunesis Pharmaceuticals is raising $43 million in a follow-on offering. Release

> Salix Pharmaceuticals ($SLXP) has struck a deal to license the worldwide rights to RedHill's RHB-106 encapsulated formulation for bowel preparation and other purgative developments. The deal includes an upfront payment of $7 million and $5 million in subsequent milestone payments to RedHill. Release

> Epizyme ($EPZM) says it has earned a $2 million milestone from its partnership with GlaxoSmithKline ($GSK). Release

> Pacira Pharmaceuticals ($PCRX) says that its Phase III study of its pain drug Exparel met its primary endpoint for femoral nerve block. Release

Medical Device News

@FierceMedDev: A proposed reform of the tax code would also repeal the 2.3% medical device tax. Naturally, the industry likes. Story | Follow @FierceMedDev

@MarkHFierce: New research suggests that pacers and the like are safe for CT scans, contrary to FDA fears. Item | Follow @MarkHFierce

@MichaelGFierce: From this week's FierceDrugDelivery report: Inner-ear delivery device sends drugs out, draws fluid in. More | Follow @MichaelGFierce

@EmilyWFierce: FDA calls for first major redrawing of food labels since the '90s, putting calorie counts front and center. Article | Follow @EmilyWFierce

> Researchers chide FDA: Pacemaker patients need not fear a CT scan. News

> FDA eyes March for Staar ocular implant review. Story

> Covidien closes its $860M Given Imaging buyout. More

Pharma News

@FiercePharma: Bayer's OTC growth march continues with pickup of China's Dihon. Story | Follow @FiercePharma

@TracyStaton: If you can't get enough of the transition at Novartis: Gist: Shareholders speak at AGM; they like the pay cuts. News (sub. req.) | Follow @TracyStaton

@EricPFierce: No sooner does Commish Hamburg return from India than the FDA reveals a new warning letter about data faking there. More | Follow @EricPFierce

@CarlyHFierce: Via FierceBiotech: Regeneron's Schleifer hits the $1B mark, but his biotech is just getting started. Article | Follow @CarlyHFierce

> FDA spying may have broken whistleblower laws, congressional probe finds. News

> FDA and EMA join forces to diffuse safety cloud over Januvia, Victoza & Co. Story

> J&J's high-stakes argument against $1.2B Risperdal fine begins in Arkansas' top court. Piece

Pharma Manufacturing News

> Mylan earnings point to reason for Agila deal. Report

> Bayer expands production in China by bagging Dihon. News

> Pfizer gets past shortage of hypothyroid drug Levoxyl. Story

> Critics call for harsher treatment of foreign drugmakers who sell faulty drugs. Article

> Doc goes to jail for lying about foreign-sourced Botox. Story

> AstraZeneca's Delaware campus sold to JPMorgan. Brief

Vaccines News

> H1N1's dominance this flu season makes quadrivalent vaccines' broader protection moot. Story

> Pfizer reports its huge trial of Prevnar has met its primary and secondary goals. News

> CDC is 'not unduly alarmed' by cases of a polio-like illness in California. Story

> Data mining study links seasonal flu vaccine to 24% drop in likelihood of stroke. Research

> MMR vaccine linked to fall in respiratory-related hospitalizations. Investigation

> Taiwan's Adimmune targets June start for mass production of bird flu vaccine. Brief

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.